Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Bavarian Nordic raises 2026 outlook after strong half-year

Bavarian Nordic reports H1 2026 revenue of DKK 3,092m and an EBITDA margin of 35%, with Q2 at 45% and a gross margin of 61%. The company raised its full-year guidance to around DKK 5.7bn and its target EBITDA margin to about 30%; the stock jumped markedly in pre-market trading. Public Preparedness is now expected at DKK 2.5bn (DKK 2.3bn contractually secured), Travel Health remains robust, and the VIMKUNYA revenue forecast for 2026 was cut to DKK 200m due to delayed US uptake. Management also announced a share buyback program of DKK 750m and highlighted strong liquidity of DKK 2.3bn and headroom for M&A. » Altro su de.investing.com
Bavarian Nordic secures government contract worth over DKK 700 million for MVA‑BN vaccine

Bavarian Nordic has received a government contract worth more than DKK 700 million for the smallpox/mpox vaccine MVA‑BN, with deliveries starting in 2026 and the bulk of revenues expected in 2027. This brings contracts in the Public Preparedness segment for 2026 to around DKK 2,200 million. The company confirms its 2026 guidance and expects Public Preparedness revenues of DKK 2,300–2,500 million and group revenues of DKK 5,500–5,700 million with an EBITDA margin of around 28%. The buyer country's identity was not disclosed; the stock last traded near its 52‑week low. » Altro su de.investing.com
Bavarian Nordic disappoints with full-year revenue guidance – shares fall after strong Q3

Bavarian Nordic reported Q3 2025 revenue up 32% to DKK 4.8bn (Q3 revenue DKK 1.8bn) and a gross margin of 50%. The company confirmed the full-year revenue guidance of DKK 6bn and an expected EBITDA margin of 26–27%, after which the share fell about 7.2% to DKK 173.6. Positive highlights include the successful market launch of the chikungunya vaccine Vincunia in ten countries and a cash position of nearly DKK 3bn. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Bavarian Nordic ha registrato ricavi pari a 271,68M€ e un utile netto di 97,88M€

(EUR)	giu 2026	YoY
Ricavi	+271,68M	22,73%
Utile lordo	+164,23M	34,11%
Utile netto	+97,88M	101,42%
EBITDA	+123,20M	68,42%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+2,16Mld€
Numero di azioni	75,68M
Massimo/minimo a 52 settimane	+32,61€ - +22,92€
Dividendi	No
Beta	0,94
Rapporto P/E	+10,82
Rapporto PEG	+1,08
Rapporto P/B	+1,23
Rapporto P/S	+2,56

Profilo aziendale

Bavarian Nordic A/S entwickelt, produziert und vermarktet lebensrettende Impfstoffe. Das Unternehmen bietet nicht replizierende Pocken- und Affenpockenimpfstoffe unter den Namen IMVAMUNE, IMVANEX und JYNNEOS, Tollwutimpfstoff für den Menschen unter dem Namen Rabipur/RabAvert, Impfstoff gegen Zeckenenzephalitis unter dem Namen Encepur und Ebola-Impfstoff unter dem Namen MVABEA an. Darüber hinaus entwickelt das Unternehmen den Impfstoff MVA-BN (gefriergetrocknet), der die klinischen Versuche der Phase III zur Behandlung von Pocken abgeschlossen hat, den Impfstoff MVA-BN RSV, der sich in den klinischen Versuchen der Phase III zur Behandlung des Respiratorischen Synzytialvirus befindet, den Impfstoff ABNCoV2, der die klinischen Versuche der Phase II zur Behandlung von SARS-CoV-2 abgeschlossen hat, und den Impfstoff TAEK-VAC, der sich in den klinischen Versuchen der Phase I/II zur Behandlung von fortgeschrittenen HER2- und Brachyury-exprimierenden Krebserkrankungen befindet. Das Unternehmen hat eine Lizenz- und Kooperationsvereinbarung mit AdaptVac sowie Lizenzvereinbarungen mit dem National Cancer Institute und dem Public Health Service. Das Unternehmen ist in den Vereinigten Staaten, Belgien, Deutschland, den Niederlanden, Schweden, der Schweiz, Österreich, dem Vereinigten Königreich, Japan und international tätig. Bavarian Nordic A/S wurde 1992 gegründet und hat seinen Hauptsitz in Hellerup, Dänemark.

Nome	Bavarian Nordic
CEO	Paul John Chaplin
Sede centrale	Hellerup, cr Danimarca
Sito web	bavarian-nordic.com
Settore	Sanità
Industria	Prodotti farmaceutici
Quotazione in borsa	03/01/2000
Dipendenti	1.861